Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome.

Alberto Giannoni Chiara Borrelli Francesco GentileGianluca MirizziMichele CoceaniUmberto ParadossiGiuseppe VergaroFrancesca BramantiGiovanni IudiceMichele EmdinClaudio Passino

Published in: European heart journal. Cardiovascular pharmacotherapy (2022)

Central apnoeas are a likely mechanism of dyspnoea and should be screened for in patients treated with ticagrelor. A drug-related sensitization of the chemoreflex may be the cause of ventilatory instability and breathlessness in this setting.

Keyphrases

acute coronary syndrome
percutaneous coronary intervention
st segment elevation myocardial infarction
st elevation myocardial infarction
antiplatelet therapy
emergency department
drug induced